Overview
- Lilly terminated the Phase 2b study that included people with Type 2 diabetes on June 10, less than a month after launch, after planning to test bimagrumab with or without tirzepatide in 180 participants.
- A separate Phase 2 trial in adults with obesity but without Type 2 diabetes remains recruiting, with an initial readout listed around April 2026.
- The move comes as regulators signal that add-on drugs should show incremental weight loss over GLP-1 therapy alone to support approval.
- Past research in diabetes raised safety questions for bimagrumab, including a pancreatitis hospitalization reported in an earlier small trial.
- Lilly shares fell roughly 2% to 4% following the disclosure, highlighting investor concern after the company’s roughly $1.9–$2 billion Versanis acquisition.